Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

IMS 2023 | The value of bispecifics in myeloma & the importance of optimally sequencing immunotherapies

Omar Nadeem, MD, Dana-Farber Cancer Institute, Boston, MA, discusses the value of bispecific antibodies as a treatment option for patients with multiple myeloma, highlighting the importance of determining the optimal sequencing of these agents alongside CAR-T cells. Dr Nadeem further discusses factors to consider when selecting between these agents, such as toxicities and patient disease profile. This interview took place at the 20th International Myeloma Society (IMS) Annual Meeting, held in Athens, Greece.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.


Advisory boards: Janssen, BMS, Takeda, Sanofi, GPCR Therapeutics, GSK